Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2982772 in moderate to severe ulcerative colitis
2016-001833-29Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK2982772 in autoimmune colitis, sponsored by GSK. Primary endpoint: Safety and tolerability of GSK2982772 60 mg multiple daily dosing. Started Jul 2016; status: completed.
02
Drugs
GSK2982772
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-001833-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001833-29.